<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02247973</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-alternative donor SCT-SAA</org_study_id>
    <nct_id>NCT02247973</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia.</brief_title>
  <official_title>PhaseⅡTrial of Co-transplantation With Bone Marrow Derived Mesenchymal Stem Cells From Related Donors in Alternative Donor Transplantation of Severe Aplastic Anemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital, Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second People's Hospital of GuangDong Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Jinan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a phase II trial designed to evaluate the efficacy and safety of&#xD;
      co-transplantation with bone marrow derived mesenchymal stem cells from related donors in&#xD;
      alternative donor transplantation of severe aplastic anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aplastic anemia (AA) is an autoimmune hematologic stem cell disease mediated by activated&#xD;
      T-lymphocytes that leads to bone marrow dysfunction. In the presence of an empty marrow,&#xD;
      pancytopenia, and transfusion dependence, the severity of the disease is based on neutrophil&#xD;
      (PMN) count: nonsevere AA (nSAA; PMN &gt; 0.5 × 109/L), severe AA (SAA;PMN 0.2- 0.5 × 109/L),&#xD;
      and very severe AA (vSAA; PMN&lt; 0.2 × 109/L).&#xD;
&#xD;
      Allogeneic BMT from an HLA-identical sibling donor or matched-alternative donor is the&#xD;
      treatment of choice for patients with aplastic anaemia.Transplantation for patients with&#xD;
      severe aplastic anaemia from an HLA identical sibling donor is now very successful with a&#xD;
      75-90% chance of long term cure and with overall survival of between 65% and 73% at 5 years&#xD;
      for matched-alternative donor transplantation. However, these two approachs are limited by&#xD;
      the availability of HLA-matched donors.&#xD;
&#xD;
      Patients without HLA-identical sibling donor or matched-alternative donor can be offered&#xD;
      immunosuppressive treatment (IST) involving injections of Anti-thymocyte globulin (ATG) in&#xD;
      combination with cyclosporine (CsA). The treatment response with ATG is at best between&#xD;
      60-80%, 30%-40% patients relapse following an initial response to treatment. Moreover, a&#xD;
      recent study has shown that on multivariate analysis of response at 6 months, only younger&#xD;
      age, absolute reticulocyte count (ARC) and absolute lymphocyte count (ALC), correlate with&#xD;
      response to ATG. Patients with SAA or vSAA, with much lower ARC and ALC, were poor response&#xD;
      to IST and have high risks of dying of infection and bleeding.&#xD;
&#xD;
      Nowadays, with advances in transplant technology, HLA-mismatched related donors and unrelated&#xD;
      donors transplantation has achieved good clinical results. Data from the XJ Huang indicated&#xD;
      that patients with HLA-mismatched related donors achieved 100% donor myeloid engraftment and&#xD;
      have a survival rate of 64.6±12.4%. Retrospectively analyzed results for 154 patients with&#xD;
      acquired SAA who received BMT from unrelated donors identified through the Japan Marrow Donor&#xD;
      Program showed the probability of OS at 5 years was 56% (95% confidence interval, 34%-78%).&#xD;
&#xD;
      Compared with malignant disease, mismatched related donor or unrelated donor HSCT for SAA&#xD;
      involves distinct challenges mainly associated with high graft failure and high GVHD. So, if&#xD;
      we can find a way to promote implantation meanwhile prevent or reduce GVHD , the efficacy of&#xD;
      HLA-mismatched related donors transplantation can improve.&#xD;
&#xD;
      Mesenchymal stem cells (MSCs) are multi-potent non-hematopoietic progenitors mainly found in&#xD;
      BM, cord blood, and adipose tissue. MSCs are attractive because of the ease with which they&#xD;
      can be isolated and expanded ex vivo, their ability to undergo multilineage differentiation,&#xD;
      and their lack of immunogenicity. These cells were shown to provide support for the growth&#xD;
      and differentiation of hematopoietic progenitor cells in BM micro-environments. In additon,&#xD;
      preliminary studies have shown clinical effectiveness of allogeneic MSC in the treatment of&#xD;
      refractory graft-versus-host disease and an improvement in or resolution of severe aGVHD when&#xD;
      co-transplantation with MSCs. Due to these properties, MSCs have become an interesting&#xD;
      candidate for use in cellular therapy and are considered &quot;theoretically perfect cells&quot; for&#xD;
      potential clinical use against AA mismatched related donors transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival rate</measure>
    <time_frame>up to 2 years after HSCT</time_frame>
    <description>The 2-year disease-free survival and overall survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute GVHD</measure>
    <time_frame>UP to 3 months after HSCT</time_frame>
    <description>The incidence of acute GVHD after HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic GVHD</measure>
    <time_frame>UP to 2 years after HSCT</time_frame>
    <description>The incidence of chronic GVHD after HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>UP to 1 months after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of relapse</measure>
    <time_frame>UP to 2 years after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The implantation</measure>
    <time_frame>Up to 4 weeks after HSCT</time_frame>
    <description>The implantation rate and implantation time.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with severe aplastic anemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal stem cells</intervention_name>
    <description>Intravenous administration of up to 1~2x10^6 MSCs per kg,for 2 times,d0 and d14</description>
    <arm_group_label>Mesenchymal stem cells</arm_group_label>
    <other_name>Multipotent Mesenchymal Stromal Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal stem cells</intervention_name>
    <description>bone marrow derived mesenchymal stem cells from related donors.</description>
    <arm_group_label>Mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. In line with the 2009 Edition (United Kingdom) aplastic anemia diagnostic criteria for&#xD;
             SAA or VSAA;&#xD;
&#xD;
          2. Age less than 50 years old,willing to transplant；&#xD;
&#xD;
          3. No HLA-identical sibling donor；&#xD;
&#xD;
          4. Have HLA-mismatched related donors or unrelated donors ( ≥5/10 HLA matched loci in&#xD;
             related donors; ≥8/10 HLA matched loci in unrelated donors )&#xD;
&#xD;
          5. No serious infection or acute hemorrhage;&#xD;
&#xD;
          6. Cardiac ultrasound examination showed left ventricular ejection fraction is greater&#xD;
             than 50%;&#xD;
&#xD;
          7. Both transaminase and serum creatinine level are no more than twice times the upper&#xD;
             limit of normal value (ULN);&#xD;
&#xD;
          8. No acute infectious disease;&#xD;
&#xD;
          9. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
         10. ECOG score of 0-2 points.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe infection or active bleeding;&#xD;
&#xD;
          2. With severe cardiac insufficiency, left ventricular ejection fraction &lt;50%;&#xD;
&#xD;
          3. With severe liver dysfunction, liver function (ALT and the TBIL) is higher than the&#xD;
             ULN 3 times;&#xD;
&#xD;
          4. With severe renal insufficiency, renal function (Cr) is twice higher than the ULN; or&#xD;
             24-hour urine creatinine clearance rate (Ccr) lower than 50ml/min;&#xD;
&#xD;
          5. Active tuberculosis, severe acute hepatitis and other infectious diseases in active&#xD;
             period;&#xD;
&#xD;
          6. ECOG score more than 3 points;&#xD;
&#xD;
          7. Accompanied by malignant tumors and other clonal disease;&#xD;
&#xD;
          8. Poor compliance and the researchers considered unsuitable for MSC infusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Xiao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Guangzhou General Hospital of Guangzhou Military Command</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou General Hospital of Guangzhou Military Command</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, Keidan J, Laurie A, Martin A, Mercieca J, Killick SB, Stewart R, Yin JA; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009 Oct;147(1):43-70. doi: 10.1111/j.1365-2141.2009.07842.x. Epub 2009 Aug 10. No abstract available.</citation>
    <PMID>19673883</PMID>
  </reference>
  <reference>
    <citation>Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socie G, Maury S, Prete A, Locasciulli A, Cesaro S, Passweg J; Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005 Dec;36(11):947-50. doi: 10.1038/sj.bmt.1705165.</citation>
    <PMID>16205733</PMID>
  </reference>
  <reference>
    <citation>Deeg HJ, O'Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA, Territo MC, Collins RH, McSweeney PA, Copelan EA, Khan SP, Woolfrey A, Storer B. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006 Sep 1;108(5):1485-91. doi: 10.1182/blood-2006-03-005041. Epub 2006 May 9.</citation>
    <PMID>16684959</PMID>
  </reference>
  <reference>
    <citation>George B, Mathews V, Viswabandya A, Lakshmi KM, Srivastava A, Chandy M. Allogeneic hematopoietic stem cell transplantation is superior to immunosuppressive therapy in Indian children with aplastic anemia--a single-center analysis of 100 patients. Pediatr Hematol Oncol. 2010 Mar;27(2):122-31. doi: 10.3109/08880010903540542.</citation>
    <PMID>20201693</PMID>
  </reference>
  <reference>
    <citation>Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A, Sakamaki H, Ikuta K, Tsuchida M, Hoshi Y, Morishima Y, Kodera Y. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002 Aug 1;100(3):799-803. doi: 10.1182/blood.v100.3.799.</citation>
    <PMID>12130489</PMID>
  </reference>
  <reference>
    <citation>Noort WA, Kruisselbrink AB, in't Anker PS, Kruger M, van Bezooijen RL, de Paus RA, Heemskerk MH, Lowik CW, Falkenburg JH, Willemze R, Fibbe WE. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol. 2002 Aug;30(8):870-8. doi: 10.1016/s0301-472x(02)00820-2.</citation>
    <PMID>12160838</PMID>
  </reference>
  <reference>
    <citation>Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004 May 1;363(9419):1439-41. doi: 10.1016/S0140-6736(04)16104-7.</citation>
    <PMID>15121408</PMID>
  </reference>
  <reference>
    <citation>Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006 May 27;81(10):1390-7. doi: 10.1097/01.tp.0000214462.63943.14.</citation>
    <PMID>16732175</PMID>
  </reference>
  <reference>
    <citation>Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008 May 10;371(9624):1579-86. doi: 10.1016/S0140-6736(08)60690-X.</citation>
    <PMID>18468541</PMID>
  </reference>
  <reference>
    <citation>Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, Locatelli F, Fibbe WE. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood. 2007 Oct 1;110(7):2764-7. doi: 10.1182/blood-2007-04-087056. Epub 2007 Jul 16.</citation>
    <PMID>17638847</PMID>
  </reference>
  <reference>
    <citation>Fang B, Li N, Song Y, Li J, Zhao RC, Ma Y. Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia. Pediatr Transplant. 2009 Jun;13(4):499-502. doi: 10.1111/j.1399-3046.2008.01002.x. Epub 2008 Jul 30.</citation>
    <PMID>18673358</PMID>
  </reference>
  <reference>
    <citation>Wang H, Wang Z, Xue M, Liu J, Yan H, Guo Z. Co-transfusion of haplo-identical hematopoietic and mesenchymal stromal cells to treat a patient with severe aplastic. Cytotherapy. 2010 Jul;12(4):563-5. doi: 10.3109/14653241003695059.</citation>
    <PMID>20380540</PMID>
  </reference>
  <reference>
    <citation>Jaganathan BG, Tisato V, Vulliamy T, Dokal I, Marsh J, Dazzi F, Bonnet D. Effects of MSC co-injection on the reconstitution of aplastic anemia patient following hematopoietic stem cell transplantation. Leukemia. 2010 Oct;24(10):1791-5. doi: 10.1038/leu.2010.164. Epub 2010 Aug 19. No abstract available.</citation>
    <PMID>20724985</PMID>
  </reference>
  <reference>
    <citation>Fang B, Song Y, Li N, Li J, Han Q, Zhao RC. Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation. Ann Hematol. 2009 Mar;88(3):261-6. doi: 10.1007/s00277-008-0599-0. Epub 2008 Sep 4.</citation>
    <PMID>18769919</PMID>
  </reference>
  <reference>
    <citation>Xiao Y, Jiang ZJ, Pang Y, Li L, Gao Y, Xiao HW, Li YH, Zhang H, Liu Q. Efficacy and safety of mesenchymal stromal cell treatment from related donors for patients with refractory aplastic anemia. Cytotherapy. 2013 Jul;15(7):760-6. doi: 10.1016/j.jcyt.2013.03.007.</citation>
    <PMID>23731760</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>September 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>September 19, 2014</last_update_submitted>
  <last_update_submitted_qc>September 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>Yang Xiao</investigator_full_name>
    <investigator_title>PhaseⅡtrial of co-transplantation with bone marrow derived mesenchymal stem cells from related donors in alternative donor transplantation of severe aplastic anemia.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02247973
org study id: MSC-alternative donor SCT-SAA
nct id: NCT02247973
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: Yes
The study is a phase II trial designed to evaluate the efficacy and safety of
      co-transplantation with bone marrow derived mesenchymal stem cells from related donors in
      alternative donor transplantation of severe aplastic anemia.
Aplastic anemia (AA) is an autoimmune hematologic stem cell disease mediated by activated
      T-lymphocytes that leads to bone marrow dysfunction. In the presence of an empty marrow,
      pancytopenia, and transfusion dependence, the severity of the disease is based on neutrophil
      (PMN) count: nonsevere AA (nSAA; PMN > 0.5 × 109/L), severe AA (SAA;PMN 0.2- 0.5 × 109/L),
      and very severe AA (vSAA; PMN< 0.2 × 109/L).

      Allogeneic BMT from an HLA-identical sibling donor or matched-alternative donor is the
      treatment of choice for patients with aplastic anaemia.Transplantation for patients with
      severe aplastic anaemia from an HLA identical sibling donor is now very successful with a
      75-90% chance of long term cure and with overall survival of between 65% and 73% at 5 years
      for matched-alternative donor transplantation. However, these two approachs are limited by
      the availability of HLA-matched donors.

      Patients without HLA-identical sibling donor or matched-alternative donor can be offered
      immunosuppressive treatment (IST) involving injections of Anti-thymocyte globulin (ATG) in
      combination with cyclosporine (CsA). The treatment response with ATG is at best between
      60-80%, 30%-40% patients relapse following an initial response to treatment. Moreover, a
      recent study has shown that on multivariate analysis of response at 6 months, only younger
      age, absolute reticulocyte count (ARC) and absolute lymphocyte count (ALC), correlate with
      response to ATG. Patients with SAA or vSAA, with much lower ARC and ALC, were poor response
      to IST and have high risks of dying of infection and bleeding.

      Nowadays, with advances in transplant technology, HLA-mismatched related donors and unrelated
      donors transplantation has achieved good clinical results. Data from the XJ Huang indicated
      that patients with HLA-mismatched related donors achieved 100% donor myeloid engraftment and
      have a survival rate of 64.6±12.4%. Retrospectively analyzed results for 154 patients with
      acquired SAA who received BMT from unrelated donors identified through the Japan Marrow Donor
      Program showed the probability of OS at 5 years was 56% (95% confidence interval, 34%-78%).

      Compared with malignant disease, mismatched related donor or unrelated donor HSCT for SAA
      involves distinct challenges mainly associated with high graft failure and high GVHD. So, if
      we can find a way to promote implantation meanwhile prevent or reduce GVHD , the efficacy of
      HLA-mismatched related donors transplantation can improve.

      Mesenchymal stem cells (MSCs) are multi-potent non-hematopoietic progenitors mainly found in
      BM, cord blood, and adipose tissue. MSCs are attractive because of the ease with which they
      can be isolated and expanded ex vivo, their ability to undergo multilineage differentiation,
      and their lack of immunogenicity. These cells were shown to provide support for the growth
      and differentiation of hematopoietic progenitor cells in BM micro-environments. In additon,
      preliminary studies have shown clinical effectiveness of allogeneic MSC in the treatment of
      refractory graft-versus-host disease and an improvement in or resolution of severe aGVHD when
      co-transplantation with MSCs. Due to these properties, MSCs have become an interesting
      candidate for use in cellular therapy and are considered "theoretically perfect cells" for
      potential clinical use against AA mismatched related donors transplantation.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: survival rate
time frame: up to 2 years after HSCT
description: The 2-year disease-free survival and overall survival.
measure: acute GVHD
time frame: UP to 3 months after HSCT
description: The incidence of acute GVHD after HSCT.
measure: chronic GVHD
time frame: UP to 2 years after HSCT
description: The incidence of chronic GVHD after HSCT.
measure: Transplant-related mortality
time frame: UP to 1 months after HSCT
measure: Rates of relapse
time frame: UP to 2 years after HSCT
measure: The implantation
time frame: Up to 4 weeks after HSCT
description: The implantation rate and implantation time.
arm group label: Mesenchymal stem cells
arm group type: Experimental
description: Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with severe aplastic anemia.
intervention type: Biological
intervention name: mesenchymal stem cells
description: Intravenous administration of up to 1~2x10^6 MSCs per kg,for 2 times,d0 and d14
arm group label: Mesenchymal stem cells
other name: Multipotent Mesenchymal Stromal Cells
intervention type: Biological
intervention name: mesenchymal stem cells
description: bone marrow derived mesenchymal stem cells from related donors.
arm group label: Mesenchymal stem cells
criteria: 
gender: All
minimum age: 14 Years
maximum age: 50 Years
healthy volunteers: No
last name: Yang Xiao, MD
role: Study Chair
affiliation: Guangzhou General Hospital of Guangzhou Military Command
facility: 
country: China
citation: Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, Keidan J, Laurie A, Martin A, Mercieca J, Killick SB, Stewart R, Yin JA; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009 Oct;147(1):43-70. doi: 10.1111/j.1365-2141.2009.07842.x. Epub 2009 Aug 10. No abstract available.
PMID: 19673883
citation: Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socie G, Maury S, Prete A, Locasciulli A, Cesaro S, Passweg J; Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005 Dec;36(11):947-50. doi: 10.1038/sj.bmt.1705165.
PMID: 16205733
citation: Deeg HJ, O'Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA, Territo MC, Collins RH, McSweeney PA, Copelan EA, Khan SP, Woolfrey A, Storer B. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006 Sep 1;108(5):1485-91. doi: 10.1182/blood-2006-03-005041. Epub 2006 May 9.
PMID: 16684959
citation: George B, Mathews V, Viswabandya A, Lakshmi KM, Srivastava A, Chandy M. Allogeneic hematopoietic stem cell transplantation is superior to immunosuppressive therapy in Indian children with aplastic anemia--a single-center analysis of 100 patients. Pediatr Hematol Oncol. 2010 Mar;27(2):122-31. doi: 10.3109/08880010903540542.
PMID: 20201693
citation: Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A, Sakamaki H, Ikuta K, Tsuchida M, Hoshi Y, Morishima Y, Kodera Y. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002 Aug 1;100(3):799-803. doi: 10.1182/blood.v100.3.799.
PMID: 12130489
citation: Noort WA, Kruisselbrink AB, in't Anker PS, Kruger M, van Bezooijen RL, de Paus RA, Heemskerk MH, Lowik CW, Falkenburg JH, Willemze R, Fibbe WE. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol. 2002 Aug;30(8):870-8. doi: 10.1016/s0301-472x(02)00820-2.
PMID: 12160838
citation: Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004 May 1;363(9419):1439-41. doi: 10.1016/S0140-6736(04)16104-7.
PMID: 15121408
citation: Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006 May 27;81(10):1390-7. doi: 10.1097/01.tp.0000214462.63943.14.
PMID: 16732175
citation: Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008 May 10;371(9624):1579-86. doi: 10.1016/S0140-6736(08)60690-X.
PMID: 18468541
citation: Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, Locatelli F, Fibbe WE. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood. 2007 Oct 1;110(7):2764-7. doi: 10.1182/blood-2007-04-087056. Epub 2007 Jul 16.
PMID: 17638847
citation: Fang B, Li N, Song Y, Li J, Zhao RC, Ma Y. Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia. Pediatr Transplant. 2009 Jun;13(4):499-502. doi: 10.1111/j.1399-3046.2008.01002.x. Epub 2008 Jul 30.
PMID: 18673358
citation: Wang H, Wang Z, Xue M, Liu J, Yan H, Guo Z. Co-transfusion of haplo-identical hematopoietic and mesenchymal stromal cells to treat a patient with severe aplastic. Cytotherapy. 2010 Jul;12(4):563-5. doi: 10.3109/14653241003695059.
PMID: 20380540
citation: Jaganathan BG, Tisato V, Vulliamy T, Dokal I, Marsh J, Dazzi F, Bonnet D. Effects of MSC co-injection on the reconstitution of aplastic anemia patient following hematopoietic stem cell transplantation. Leukemia. 2010 Oct;24(10):1791-5. doi: 10.1038/leu.2010.164. Epub 2010 Aug 19. No abstract available.
PMID: 20724985
citation: Fang B, Song Y, Li N, Li J, Han Q, Zhao RC. Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation. Ann Hematol. 2009 Mar;88(3):261-6. doi: 10.1007/s00277-008-0599-0. Epub 2008 Sep 4.
PMID: 18769919
citation: Xiao Y, Jiang ZJ, Pang Y, Li L, Gao Y, Xiao HW, Li YH, Zhang H, Liu Q. Efficacy and safety of mesenchymal stromal cell treatment from related donors for patients with refractory aplastic anemia. Cytotherapy. 2013 Jul;15(7):760-6. doi: 10.1016/j.jcyt.2013.03.007.
PMID: 23731760
responsible party type: Principal Investigator
investigator affiliation: Guangzhou General Hospital of Guangzhou Military Command
investigator full name: Yang Xiao
investigator title: PhaseⅡtrial of co-transplantation with bone marrow derived mesenchymal stem cells from related donors in alternative donor transplantation of severe aplastic anemia.
mesh term: Anemia
mesh term: Anemia, Aplastic